Latest Lenalidomide Stories
The Oncology Institute of Hope and Innovation is pleased to announce the recent openings of clinical trials this holiday season. Downey, CA (PRWEB) November
Data from 13 accepted abstracts include: NORTH CHICAGO, Ill., Nov.
Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company's Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND
- Note: This release corresponds to ASH abstracts 22, 31, 78, 84, 176, 327, 505, 2096, 2312, 3448, 3474, 4454, 4469, 4680 RARITAN, N.J., Nov.
NORWALK, Conn., Sept.
CORAL SPRINGS, Florida, September 19, 2014 /PRNewswire/ -- BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of
WHITE PLAINS, N.Y., Aug.
Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug.
Emerging Therapies are Not Expected to Offer Improvements in Safety and Tolerability Attributes, According to Findings from Decision Resources Group BURLINGTON, Mass., April 10, 2014 /PRNewswire/
Poor Efficacy and Physicians' Desire for Personalized Therapeutics Will Provide Opportunity for Developers of New Therapies, According to Findings from Decision Resources Group BURLINGTON,
- An armed gangster.